Cell cycle and dystrophin dysregulation in GIST.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

1. A unified model for Duchenne muscular dystrophy gene involvement in cancer: context-dependent tumour suppression and oncogenicity.FEBS open bio · 2026
   Article
2. The Duchenne muscular dystrophy gene and cancer.Cellular oncology (Dordrecht, Netherlands) · 2021
   Review
3. Preclinical model-based evaluation of Imatinib resistance induced byAmerican journal of translational research · 2021
   Article
4. Genomic aberrations in cell cycle genes predict progression ofClinical sarcoma research · 2019
   Article
5. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.Oncotarget · 2017
   Review

Corrections and comments

• Comment on
  Dystrophin is a tumor suppressor in human cancers with myogenic programs.2014

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as